...
首页> 外文期刊>Cancer Cell International >The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment
【24h】

The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment

机译:介导特异性DNA转移的嵌合多域蛋白可治疗肝细胞癌

获取原文
           

摘要

Aim This study was aimed to evaluate the therapeutic efficiency of a non-virus based specific chimeric multi-domain DNA transferred with apoptin in human hepatocellular carcinoma (HCC) HepG-2 cells in vitro and in mice H22 cells in vivo. Methods We firstly constructed the multi-domain recombinant chimeric proteins based on recombinant proteins [G (yeast GAL4), NG (none GAL4), TG (GAL4?+?Tat protein) and TNG (Tat protein)] and pUAS-Apoptin plasmid, and transfected them into human HepG-2 cells. The antitumor effect of this multi-domain recombinant chimeric proteins to HCC cells were detected by MTT assay, AO/EB staining, DAPI staining and Annexin V assay. In order to find the pathway of cell apoptosis, the Caspase (1, 3, 6 and 8) activity was detected. We then constructed the H22 liver cancer mice model and analyzed the anti-tumor rate and mice survival rate after treated with G/pUAS-Apoptin NG/pUAS-Apoptin TG/pUAS-Apoptin, and TNG/pUAS-Apoptin. Results MTT results showed that the Tat protein (TG and TNG) significantly induced cell death in a time dependent manner. AO/EB, DAPI, Annexin V and Caspases assay results indicated that the Caspase 1, 3, 6 and 8 were highly expressed in TG/pUAS-Apoptin, and TNG/pUAS-Apoptin treated mouse groups. The antitumor rate and survival rate in TG/pUAS-Apoptin, and TNG/pUAS-Apoptin treated mouse groups were higher than in the other groups. Conclusion The Tat-apoptin is a potential anti-tumor agent for HCC treatment with remarkable anti-tumor efficacy and high safety based on non-virus gene transfer system. The anti-tumor function may be associated with high expression of Caspase 1, 3, 6 and 8.
机译:目的这项研究旨在评估载有凋亡蛋白的非病毒特异性嵌合多结构域DNA在人肝细胞癌(HCC)HepG-2细胞中体外和在小鼠H22细胞中的治疗效果。方法我们首先基于重组蛋白[G(酵母GAL4),NG(无GAL4),TG(GAL4α+βTat蛋白)和TNG(Tat蛋白)]和pUAS-Apoptin质粒构建了多域重组嵌合蛋白,并将它们转染到人类HepG-2细胞中。通过MTT测定,AO / EB染色,DAPI染色和膜联蛋白V测定法检测该多结构域重组嵌合蛋白对HCC细胞的抗肿瘤作用。为了找到细胞凋亡的途径,检测了Caspase(1、3、6和8)活性。然后,我们构建了H22肝癌小鼠模型,并分析了用G / pUAS-Apoptin NG / pUAS-Apoptin TG / pUAS-Apoptin和TNG / pUAS-Apoptin处理后的抗肿瘤率和小鼠存活率。结果MTT结果表明Tat蛋白(TG和TNG)以时间依赖性方式显着诱导细胞死亡。 AO / EB,DAPI,Annexin V和Caspases检测结果表明,胱天蛋白酶1、3、6和8在TG / pUAS-Apoptin和TNG / pUAS-Apoptin处理的小鼠组中高表达。 TG / pUAS-Apoptin和TNG / pUAS-Apoptin处理的小鼠组的抗肿瘤率和存活率均高于其他组。结论基于非病毒基因转移系统,Tat-apoptin是一种潜在的HCC抗肿瘤药物,具有显着的抗肿瘤作用,安全性高。抗肿瘤功能可能与Caspase 1、3、6和8的高表达有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号